Compare Box Inc (BOX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Gilead Sciences, Inc. — how do they compare? Box Inc trades at $32.86 (market cap $4.65B), while Gilead Sciences, Inc. trades at $135.49 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 35.5× Box Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Box Inc pays none. Which is the better fit depends on your goals.
| BOX | GILD | |
|---|---|---|
Market Cap | $4.65B | $164.99B |
Sector | Technology | Health |
52-Week High | $33.60 | $155.80 |
52-Week Low | $21.37 | $110.56 |
Enterprise Value | $5.21B | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX Inc. (NYSE: BOX) trades at $33.24, up 4.36% today, showing strong momentum near resistance levels. The company delivered solid Q1 2026 earnings beat with EPS of $0.37 versus $0.36 expected, continuing positive earnings surprises. Revenue growth accelerated to $1.09 billion in 2025 with net income margin expanding to 22.43%. Technical indicators show bullish momentum with the stock trading above key support levels and moving averages signaling strength.
BOX presents growth potential with strong revenue expansion and improving profitability, supported by recent enterprise contract wins like Quintas Energy's AI platform selection. However, elevated P/E ratio of 51.94 suggests premium valuation, while negative equity and high debt levels warrant monitoring. Analyst consensus remains bullish with $37 price target, representing 11% upside from current levels.
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
